Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV

Exclusion Criteria

• •Have received any type of zoster vaccine within 1 year.
• •Have been diagnosed with chickenpox or shingles within 12 months.
• •Have a history of severe allergy to any of the components of Shingrix vaccine.
• •Have a acute medical condition at the time of screening.
• •Unable to be evaluated for adverse events via telephone contact after vaccination.
• •Pregnant (including those planning to become pregnant) or lactating women.
• •Those who have received chemotherapy or radiotherapy within 6 months prior to the first vaccine dose.
• •Chronic administration of immunosuppressive or other immune-modifying drugs within 6 months prior to ther first vaccine dose.
• •Administration of immunoglobulins, and/or any blood products within 3 months preceding the first dose of study vaccine
• •Have a medical condition that makes receiving an intramuscular injection medically contraindicated.
• •Have a disease or condition that may affect the immunogenicity or safety of the vaccine.
• •Receiving any other vaccine within 14 days prior to and 14 days after receiving the study vaccine.
• •Participate in a clinical trial that involves other investigational product or device during the course of the study.
• •Any other person who, in the opinion of the investigator, is unsuitable for immune response assessment.